Drug intelligence / Profile preview

betamethasone + hydrocortisone butyrate + mometasone

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Topical

Overview

This is a combination of three different topical corticosteroids (betamethasone, hydrocortisone butyrate, and mometasone) that are not typically formulated together as a single product. Each is a synthetic corticosteroid with different potencies used to treat inflammatory skin conditions. They work by binding to glucocorticoid receptors to reduce inflammation, inhibit inflammatory mediators, and block transcription factors involved in inflammation.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on betamethasone + hydrocortisone butyrate + mometasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + hydrocortisone butyrate + mometasone.

Explore the full profile